After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and ...

Key Insights Significantly high institutional ownership implies GSK's stock price is sensitive to their trading ...

Glancy Prongay & Murray LLP reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Law Offices of Howard G. Smith reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased GSK plc. ("GSK" or the ...

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...